Figure 4.

Comparison of the levels of various biomarkers in the SLE patients visits with mycophenolate mofetil (MMF) therapy versus untreated. Data were analyzed as in Figure 1 except only patients receiving MMF in the treated patient population were included. (A) Disease activity, (B-C) complement levels, (D) anti-dsDNA antibody levels, (E) IFN Score, (F) ADAR, (G) STAT1, (H) CCL2, (I) CXCL10, (J) miR-146a, (K) pri-miR-146a, and (L) TNFα in treated (Tx) and untreated (UTX) SLE patient visits as well as healthy donors (HD). Data are presented as box plot. All groups were compared among each other and only significant P values are shown indicating each specific comparison. Average trend lines for high STAT1 (blue) and low STAT1 (red) patient visit subsets are also shown for comparison. Detail comparison between high and low STAT1 subsets are shown in Additional file 1: Figure S5. ADAR, adenosine deaminase acting on RNA; CCL2, C-C motif chemokine ligand 2; CXCL10, C-X-C motif chemokine 10; dsDNA, double-stranded DNA; IFN, interferon; SLE, systemic lupus erythematosus; STAT1, signal transducer and activator of transcription 1; TNFα, tumor necrosis factor alpha.